Content about Research

March 12, 2014

The Pharmaceutical Research and Manufacturers of America and the National Minority Quality Forum announced on Wednesday a first-of-its-kind national campaign to help increase diversity in clinical trials.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America and the National Minority Quality Forum announced on Wednesday a first-of-its-kind national campaign to help increase diversity in clinical trials.

January 8, 2014

Takeda Pharmaceutical has started a late-stage clinical trial program of its experimental drug for inflammatory bowel disease in Japan, the company said Wednesday.

OSAKA, Japan — Takeda Pharmaceutical has started a late-stage clinical trial program of its experimental drug for inflammatory bowel disease in Japan, the company said Wednesday.

Takeda announced the start of two phase-3 trials of MLN0002 (vedolizumab) in patients with severe ulcerative colitis and Crohn's disease. The trials are designed to find out the efficacy, safety and effects on the body of the drug, particularly to see if patients show a response after 10 weeks of treatment and disease remission after 60 weeks.

December 10, 2013

NEW YORK — Absorption Pharmaceuticals will be conducting clinical trials with Kaiser to measure the efficacy of the company's over-the-counter solution for PE Promescent, CNBC reported Tuesday.

NEW YORK — Absorption Pharmaceuticals will be conducting clinical trials with Kaiser to measure the efficacy of the company's over-the-counter solution for PE Promescent, CNBC reported Tuesday. 

Beginning next week, Kaiser will follow 150 men who suffer from premature ejaculation and will be given either Promescent or a placebo over the course of the next year. Patients are being recruited from the San Diego and Los Angeles markets, according to the report.  

December 9, 2013

The Food and Drug Administration's Office of Generic Drugs will be elevated to a "super office," a top official in the agency told staff members in a memo Monday.

WASHINGTON — The Food and Drug Administration's Office of Generic Drugs will be elevated to a "super office," a top official in the agency told staff members in a memo Monday.

November 11, 2013

AccentHealth collected data through an online survey conducted from Oct. 14 to 21. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 520 respondents who were at least 18 years of age, and either themselves or a household member have prediabetes, Type 1 diabetes or Type 2 diabetes.

AccentHealth collected data through an online survey conducted from Oct. 14 to 21. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 520 respondents who were at least 18 years of age, and either themselves or a household member have prediabetes, Type 1 diabetes or Type 2 diabetes.

All data is self-reported and not validated.

Below is the demographic breakdown of the respondents and their behavior:

Gender

November 5, 2013

A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

LAKE FOREST, Ill. — A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

September 12, 2013

AccentHealth collected data through an online survey conducted from Aug. 21 to 27, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 501 respondents who were at least 18 years of age.

AccentHealth collected data through an online survey conducted from Aug. 21 to 27, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 501 respondents who were at least 18 years of age.

All data is self-reported and not validated.

Below is the demographic breakdown of the respondents and their behavior:

Gender

 

August 14, 2013

AccentHealth collected data through an online survey conducted from July 10 to 16, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 512 respondents who were at least 18 years of age and have a child in school (i.e., elementary, middle or high school) or college.

AccentHealth collected data through an online survey conducted from July 10 to 16, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 512 respondents who were at least 18 years of age and have a child in school (i.e., elementary, middle or high school) or college.

All data is self-reported and not validated.

Below is the demographic breakdown of the respondents and their behavior:

Gender

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

NEW YORK — Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

In a draft guidance released Friday, the FDA said that due to the efficacy profile of Allergan's drug for dry eyes Restasis (cyclosporine) ophthalmic emulsion, it wouldn't be effective for companies to conduct clinical trials to determine the efficacy of a generic version.

May 9, 2013

AccentHealth collected data through an online survey conducted from Feb. 13 to 15, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 644 respondents who were at least 18 years of age and owned either a smartphone, cell phone with Internet access or a tablet.

AccentHealth collected data through an online survey conducted from April 16 to 18, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 698 respondents who were at least 18 years of age.

All data is self-reported and not validated.

Below is the demographic breakdown of the respondents and their behavior:

Gender

 

April 23, 2013

The Food and Drug Administration has approved a new contraceptive drug made by Warner Chilcott, the drug maker said.

DUBLIN — The Food and Drug Administration has approved a new contraceptive drug made by Warner Chilcott, the drug maker said.

Warner Chilcott announced the approval of Minastrin 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for prevention of pregnancy.

The drug maker said an unnamed third-party company would manufacture the drug, but it did not expect to launch it this year.

 

March 11, 2013

AccentHealth collected data through an online survey conducted from Feb. 13 to 15, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 644 respondents who were at least 18 years of age and owned either a smartphone, cell phone with Internet access or a tablet.

AccentHealth collected data through an online survey conducted from Feb. 13 to 15, 2013. Participants responded via AccentHealth's national, online panel of network viewers, and the survey yielded 644 respondents who were at least 18 years of age and owned either a smartphone, cell phone with Internet access or a tablet.

All data is self-reported and not validated.

Below is the demographic breakdown of the respondents and their behavior:

 

Gender

February 12, 2013

Unexpected toxicities from prescription drugs that emerge years after regulatory approval may be due to poor medication adherence in clinical trials, according to a new study.

MCLEAN, Va. — Unexpected toxicities from prescription drugs that emerge years after regulatory approval may be due to poor medication adherence in clinical trials, according to a new study.

While much attention on medication adherence has focused on patients not taking the already approved drugs prescribed to them or not taking them properly, the new study, released Tuesday by Consumer Health Information, found problems with adherence in clinical trials as well.

January 8, 2013

Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

SAN FRANCISCO — Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

The 2013 California Biomedical Industry Report — by PwC, the California Healthcare Institute and BayBio — looked at California's biotech industry and how it faired in 2012.

December 3, 2012

Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

WHITEHOUSE STATION, N.J. — Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

Merck announced the start of "EPOCH," a combined phase-2 and phase-3 study of the drug MK-8931, a 78-week trial in which patients will take either the drug in the 12-mg, 40-mg or 60-mg doses or placebo.

October 31, 2012

Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

HOLZKIRCHEN, Germany — Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, said it had started enrolling patients for a phase-3 study of epoetin alfa, a biosimilar version of Epogen and Procrit, made by Amgen and Johnson & Johnson and used to treat anemia associated with chronic kidney disease.

October 26, 2012

AccentHealth collected data through an online survey conducted from Sept. 18 to Sept. 30, 2012. There were a total of 940 people who responded via AccentHealth's national, online panel of network viewers ages 18 years and up who opt-in to participate in reasearch with AccentHealth.

AccentHealth collected data through an online survey conducted from Sept. 18 to Sept. 30, 2012. There were a total of 940 people who responded via AccentHealth's national, online panel of network viewers ages 18 years and up who opt-in to participate in reasearch with AccentHealth.

All data is self-reported and not validated using medical records.

Below is the demographic breakdown of the respondents and their behavior:

 

Gender

October 18, 2012

The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.

SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.

The agency announced the approval of Jetrea (ocriplasmin), made by Iselin, N.J.-based ThromboGenics. The drug is used to treat symptomatic vitreomacular adhesion.

September 28, 2012

Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

BOTHELL, Wash. — Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

OncoGenex announced Friday the initiation of the phase-3 "ENSPIRIT" trial of custirsen in patients with nonsmall cell lung cancer that has spread to other parts of the body, also known as metastasis, and whose disease has progressed after initial treatment with chemotherapy has failed.

September 13, 2012

The Food and Drug Administration has approved a new drug for multiple sclerosis.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new drug for multiple sclerosis.

Sanofi subsidiary Genzyme announced that the FDA had approved Aubagio (teriflunomide) as a once-daily, oral treatment for patients with relapsing MS.

September 10, 2012

A study of an experimental drug for insomnia indicated that patients who stop taking it continue having sleeping problems, according to results of a clinical trial announced Monday.

WHITEHOUSE STATION, N.J. — A study of an experimental drug for insomnia indicated that patients who stop taking it continue having sleeping problems, according to results of a clinical trial announced Monday.

Merck released data from a phase-3 trial of suvorexant in which patients who had been taking the drug daily for a year were switched to placebo for a two-month "discontinuation phase." Patients who were switched from the drug to placebo showed sleeping difficulties similar to those who had consistently taken placebo.

August 29, 2012

The Food and Drug Administration has granted priority review to a supplemental new drug application for a drug developed by Janssen Research and Development.

RARITAN, N.J. — The Food and Drug Administration has granted priority review to a supplemental new drug application for a drug developed by Janssen Research and Development.

August 27, 2012

AccentHealth collected data through an online survey conducted from July 19 to Aug. 1, 2012. There were a total of 745 respondents who were recruited via AccentHealth's national, online panel of network viewers ages 18 years and up who opt-in to participate in reasearch with AccentHealth.

AccentHealth collected data through an online survey conducted from July 19 to Aug. 1, 2012. There were a total of 745 respondents who were recruited via AccentHealth's national, online panel of network viewers ages 18 years and up who opt-in to participate in reasearch with AccentHealth. Below is the demographic breakdown of those respondents and their behavior:

Number of annual pharmacy visits

 

April 25, 2012

Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.

THOUSAND OAKS, Calif. — Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.

Amgen said it would acquire 95.6% of Istanbul-based Mustafa Nevzat for $700 million in an all-cash deal, saying the purchase would allow it to expand in Turkey and the surrounding region. The company, also known as MN, is a major supplier of injectable drugs in Turkey and, increasingly, an exporter of medicines.

April 24, 2012

Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

SILVER SPRING, Md. — Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

The Food and Drug Administration released a report Monday detailing its strategies for what it called transforming from a domestic to a global public health agency.